Protecting those who suffer from peanut allergy
Peanut allergy is a life-threatening disease with only one approved medical treatment option, which may not be suitable for some peanut allergy sufferers due to side effects and potential safety issues. Avoidance of peanut consumption is typically practiced by affected individuals, coupled with reliance on antihistamines or epinephrine injection in the event of symptoms triggered by accidental exposure. Strict dietary avoidance is often expensive and hard to achieve and accidental exposure to peanut allergens is common.
INT301 is the initial product in development by Intrommune specifically designed to help those who suffer from peanut allergy. The product is intended to significantly raise a patient’s immune threshold through daily use of OMIT toothpaste beyond what has triggered a potentially dangerous allergic reaction via accidental exposure. This additional protection helps relieve the persistent anxiety of peanut allergic individuals toward accidental exposure.
Peanut INT301: OMEGA Clinical Trial
Intrommune’s Phase 1 OMEGA Clinical Trial was a 48-week, double-blind, placebo-controlled trial involving 32 adult patients with peanut allergy to assess the safety of INT301. Please visit our News & Resources page to stay up-to-date on our progress and be the first to know when we embark on Phase 2.